Susquehanna International Group
AVDL

Susquehanna International Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Susquehanna International Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-238,800
Closed -$5.15M – 13143
2025
Q4 		$5.15M Buy
238,800
+99,200
+71% +$1.93M ﹤0.01% 3972
2025
Q3 		$2.13M Sell
139,600
-67,400
-33% -$877K ﹤0.01% 5638
2025
Q2 		$1.83M Buy
207,000
+50,400
+32% +$443K ﹤0.01% 5981
2025
Q1 		$1.23M Sell
156,600
-64,000
-29% -$536K ﹤0.01% 6743
2024
Q4 		$2.32M Buy
220,600
+148,100
+204% +$1.8M ﹤0.01% 4972
2024
Q3 		$951K Sell
72,500
-24,500
-25% -$373K ﹤0.01% 6898
2024
Q2 		$1.36M Sell
97,000
-1,656,800
-94% -$27M ﹤0.01% 5870
2024
Q1 		$29.6M Buy
1,753,800
+1,690,400
+2,666% +$25.2M 0.01% 1414
2023
Q4 		$895K Sell
63,400
-4,400
-6% -$51.7K ﹤0.01% 7254
2023
Q3 		$698K Sell
67,800
-250,900
-79% -$3.36M ﹤0.01% 7453
2023
Q2 		$5.25M Buy
318,700
+124,300
+64% +$1.62M ﹤0.01% 3448
2023
Q1 		$1.78M Sell
194,400
-83,100
-30% -$683K ﹤0.01% 5397
2022
Q4 		$1.99M Sell
277,500
-98,200
-26% -$689K ﹤0.01% 4715
2022
Q3 		$1.88M Buy
375,700
+111,500
+42% +$614K ﹤0.01% 5028
2022
Q2 		$645K Buy
264,200
+101,400
+62% +$416K ﹤0.01% 7642
2022
Q1 		$1.11M Buy
162,800
+92,900
+133% +$639K ﹤0.01% 6845
2021
Q4 		$565K Sell
69,900
-52,700
-43% -$482K ﹤0.01% 8848
2021
Q3 		$1.2M Sell
122,600
-17,300
-12% -$136K ﹤0.01% 7069
2021
Q2 		$942K Buy
139,900
+65,300
+88% +$519K ﹤0.01% 7935
2021
Q1 		$674K Buy
74,600
+23,900
+47% +$193K ﹤0.01% 8764
2020
Q4 		$339K Sell
50,700
-42,700
-46% -$267K ﹤0.01% 9030
2020
Q3 		$471K Buy
93,400
+41,400
+80% +$301K ﹤0.01% 7810
2020
Q2 		$420K Buy
52,000
+7,200
+16% +$63.5K ﹤0.01% 7739
2020
Q1 		$356K Sell
44,800
-122,400
-73% -$940K ﹤0.01% 7644
2019
Q4 		$1.26M Buy
167,200
+147,300
+740% +$778K ﹤0.01% 5079
2019
Q3 		$83K Buy
+19,900
New +$49.8K ﹤0.01% 9640
2019
Q1 		– Sell
-20,800
Closed -$54K – 8794
2018
Q4 		$54K Sell
20,800
-22,000
-51% -$74.8K ﹤0.01% 8454
2018
Q3 		$188K Sell
42,800
-7,400
-15% -$40K ﹤0.01% 8264
2018
Q2 		$308K Sell
50,200
-27,900
-36% -$196K ﹤0.01% 7782
2018
Q1 		$569K Buy
78,100
+47,100
+152% +$414K ﹤0.01% 6367
2017
Q4 		$254K Buy
31,000
+16,000
+107% +$150K ﹤0.01% 7862
2017
Q3 		$158K Buy
+15,000
New +$143K ﹤0.01% 8161
2016
Q4 		– Sell
-23,200
Closed -$288K – 9544
2016
Q3 		$288K Sell
23,200
-100
-0.4% -$1.31K ﹤0.01% 6994
2016
Q2 		$250K Buy
+23,300
New +$248K ﹤0.01% 7255
2015
Q4 		– Sell
-46,900
Closed -$765K – 9393
2015
Q3 		$765K Buy
46,900
+14,000
+43% +$308K ﹤0.01% 6280
2015
Q2 		$697K Sell
32,900
-13,100
-28% -$235K ﹤0.01% 6961
2015
Q1 		$827K Buy
46,000
+3,400
+8% +$53.2K ﹤0.01% 6133
2014
Q4 		$730K Buy
42,600
+11,100
+35% +$159K ﹤0.01% 6474
2014
Q3 		$451K Sell
31,500
-207,700
-87% -$2.99M ﹤0.01% 7394
2014
Q2 		$3.59M Buy
239,200
+178,300
+293% +$2.15M ﹤0.01% 3605
2014
Q1 		$816K Buy
+60,900
New +$653K ﹤0.01% 5869
2013
Q3 		– Sell
-11,600
Closed -$71K – 8374
2013
Q2 		$71K Buy
+11,600
New +$59.9K ﹤0.01% 7891

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Susquehanna International Group's AVDL Position: Q1 2026 in Review

Susquehanna International Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 61,690 shares — an estimated $1.33M sold.

Susquehanna International Group first reported a position in AVDL in Q2 2013 and held it in 41 quarters. The position peaked at $4.61M in Q2 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Susquehanna International Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 61,690 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.33M.
  • Susquehanna International Group first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 41 quarters.
  • Susquehanna International Group's Avadel Pharmaceuticals position peaked at $4.61M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.